Answer
Co-administration with ketoconazole increases exposure (AUC) to fingolimod hydrochloride (Gilenya) and its active metabolite, fingolimod phosphate, 1.7-fold through inhibition of CYP4F2.
Sources for this answer
- Gilenya 0.25mg and 0.5mg hard capsulesNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 37Document updated
Sources checked